EAM
IART icon

Empirical Asset Management’s Integra LifeSciences IART Stock Holding History

Empirical Asset Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,862
Closed -$212K – 286
2023
Q4 		$212K Buy
+4,862
New +$191K 0.17% 168

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Empirical Asset Management's IART Position: Q1 2024 in Review

Empirical Asset Management sold out of Integra LifeSciences (IART) in Q1 2024, closing a stake of 4,862 shares — an estimated $212K sold.

Empirical Asset Management first reported a position in IART in Q4 2023 and held it in 1 quarter. The position peaked at $212K in Q4 2023. 281 funds tracked by Wall St. Rank hold IART as of Q1 2024.

  • Empirical Asset Management reported no remaining Integra LifeSciences position as of Q1 2024 after selling out during the quarter.
  • Empirical Asset Management sold 4,862 Integra LifeSciences shares in Q1 2024, an estimated $212K.
  • Empirical Asset Management first reported a position in Integra LifeSciences in Q4 2023 and held it in 1 quarter.
  • Empirical Asset Management's Integra LifeSciences position peaked at $212K in Q4 2023.
  • 281 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2024.

Based on Empirical Asset Management's 13F filing for Q1 2024, filed 10 May 2024.